Phase 4Completed
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 10 enrolled
- Conditions
- Renal Angiomyolipoma
- Interventions
- Everolimus
- Ages
- adults, older adults
- Registry
- NCT05252585
Full record on ClinicalTrials.gov
From the registry
The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) . Only patients who fulfil the local reimbursement criteria of everolimus for TSC-AML will be included in this study.
Primary outcomes
- Percentage of participants with adverse events (AEs), Serious AEs (SAEs) and AEs of special interest (AESI)
History
Enrollment up to 10
, from 4 to 10
Last registry update
Completed
, from Active, not recruiting to Completed
Primary completion
Started
Registered